1. Home
  2. IMNN vs BNKK Comparison

IMNN vs BNKK Comparison

Compare IMNN & BNKK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$1.51

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

BNKK

Bonk Inc.

HOLD

Current Price

$1.12

Market Cap

9.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNN
BNKK
Founded
1982
2018
Country
United States
United States
Employees
N/A
10
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
9.4M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
IMNN
BNKK
Price
$1.51
$1.12
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
94.8K
78.0K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.53
$0.11
52 Week High
$9.18
$7.19

Technical Indicators

Market Signals
Indicator
IMNN
BNKK
Relative Strength Index (RSI) 28.12 30.67
Support Level N/A $0.12
Resistance Level $2.18 $1.66
Average True Range (ATR) 0.15 0.08
MACD -0.03 0.00
Stochastic Oscillator 3.17 0.00

Price Performance

Historical Comparison
IMNN
BNKK

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

About BNKK Bonk Inc.

Bonk Inc provides over-the-counter products and consumer products in the United States. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It sells its products through direct customers, distributors, retailers, and e-commerce websites. The company generates revenue through various channels, its primary sales include nostingz suncare products which are sold through e-commerce platforms, licensing revenues from Photocil and sales of the Safety Shot Beverage. The company has two reportable segments: the dietary and energy beverage business and digital assets, consisting of investing for growth in the appreciation of the asset. It derives the majority of the revenue from the dietary and energy beverage segment.

Share on Social Networks: